- Home
- LIEN vs ABEO Comparison
LIEN vs ABEO Comparison
Compare LIEN & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- ABEO
- Stock Information
- Founded
- LIEN 2021
- ABEO 1974
- Country
- LIEN United States
- ABEO United States
- Employees
- LIEN N/A
- ABEO N/A
- Industry
- LIEN
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- LIEN
- ABEO Health Care
- Exchange
- LIEN NYSE
- ABEO Nasdaq
- Market Cap
- LIEN 234.6M
- ABEO 256.9M
- IPO Year
- LIEN 2022
- ABEO 1980
- Fundamental
- Price
- LIEN $10.75
- ABEO $5.69
- Analyst Decision
- LIEN Buy
- ABEO Strong Buy
- Analyst Count
- LIEN 2
- ABEO 6
- Target Price
- LIEN N/A
- ABEO $18.00
- AVG Volume (30 Days)
- LIEN 61.1K
- ABEO 1.1M
- Earning Date
- LIEN 08-07-2025
- ABEO 08-11-2025
- Dividend Yield
- LIEN 12.53%
- ABEO N/A
- EPS Growth
- LIEN 30.25
- ABEO N/A
- EPS
- LIEN 1.15
- ABEO N/A
- Revenue
- LIEN $30,828,508.00
- ABEO N/A
- Revenue This Year
- LIEN $154.46
- ABEO N/A
- Revenue Next Year
- LIEN $10.64
- ABEO $323.51
- P/E Ratio
- LIEN $9.29
- ABEO N/A
- Revenue Growth
- LIEN 151.96
- ABEO N/A
- 52 Week Low
- LIEN $9.70
- ABEO $3.93
- 52 Week High
- LIEN $13.38
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- ABEO 47.54
- Support Level
- LIEN N/A
- ABEO $5.68
- Resistance Level
- LIEN N/A
- ABEO $5.93
- Average True Range (ATR)
- LIEN 0.00
- ABEO 0.26
- MACD
- LIEN 0.00
- ABEO -0.01
- Stochastic Oscillator
- LIEN 0.00
- ABEO 56.25
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.